Release Date: December 10, 2022
Release Date: February 1, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward hematologists, medical oncologists, hematologic oncologists, hematopathologists, and other healthcare professionals involved in the treatment of hemolytic anemias.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine the pathophysiological mechanisms of the rare hemolytic anemias PNH, aHUS, PKD, wAIHA, and aplastic anemia (AA)
- Explain recent diagnostic criteria for PNH, aHUS, PKD, wAIHA, and AA, with a focus on differential diagnosis methods
- Evaluate efficacy/safety data on current and emerging therapeutic options for PNH, aHUS, PKD, wAIHA, and AA
- Apply evidence from pivotal trials that assessed therapeutic options for hemolytic anemias to manage real-world clinical scenarios of patients with these diseases, including treatment-related toxicity management
Carlos M. De Castro III, MD
Professor of Medicine
Duke University Medical Center
Durham, NC
Disclosures: Consultant: Novartis, Biocryst. Speakers’ Bureau: Apellis Pharmaceuticals, Alexion Pharmaceuticals. Other: DSMB - Regeneron.
Ara Metjian, MD
Associate Professor
University of Colorado Anschutz School of Medicine
Aurora, CO
Caroline Piatek, MD
Associate Professor, Jane Anne Nohl Division of Hematology
USC Norris Comprehensive Cancer Center
Los Angeles, CA
Disclosures: Consultant: Rigel Pharmaceuticals
Jennifer Rothman, MD
Director, Pediatric Comprehensive Sickle Cell Program
Duke University Medical Center
Durham, NC
Disclosures: Grant/Research Support: Agios Pharmaceuticals, Novartis, Pfizer, Sobi, Dova, Sanofi. Consultant: Agios Pharmaceuticals, Sobi, Novartis.
Phillip Scheinberg, MD, PhD
Chief of Clinical Hematology
Hospital A Beneficencia Portuguesa
Sao Paulo, Brazil
Disclosures: Grant/Research Support: Pfizer, Alnylam. Consultant: Novartis, AbbVie, Roche, Alexion, Pfizer, Biocryst, AstraZeneca. Speakers’ Bureau: Novartis, Pfizer, Alexion, AstraZeneca, Amgen, Bristol Myers Squibb
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
